Regulatory Approvals

Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer

By

Regulatory Approvals — Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer  Targeted Oncology

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 19, 2026.

By

Related Post

Regulatory Approvals

Haemonetics says FDA clears vascular closure device

Regulatory Approvals

FDA Approves Ryzumvi Eye Drops for Presbyopia

Regulatory Approvals

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery

Financial News For All

Regulatory Approvals

Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer

Regulatory Approvals

FDA Approves Ryzumvi Eye Drops for Presbyopia

Regulatory Approvals

Haemonetics says FDA clears vascular closure device

Regulatory Approvals

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery